Authors' Reports

A.A van Bodegraven
describes for SIIC the most significant aspects of his article
describe para SIIC los aspectos relevantes de su artículo

Changes in local and systemic inflammation-associated cytokines due to Inflammatory Bowel Disease influence the health of bone.
Inflammatory bowel disease and associated extra-intestinal inflammation of bone

Inflammatory bowel disease (IBD) is associated with nutritional deficiencies, decreased absorption of nutrients, decreased physical activity. (Active) IBD leads to increased generation of a mixture of inflammatory cytokines, potentially detrimental for bone, as is the commonly used corticosteroid treatment of IBD. These factors together induce osteoporosis and increased bone fracture risk. Bone-protecting strategies are being suggested.

The article was published by
El artículo fue publicado por
Osteoporosis International
Volume / Volumen: 31
Number / Número: 4
First and last pages / Páginas inicial-final: 637-646
Year / Año: 2020
Month / Mes: april

Principal institution where the research took place
Institución principal de la investigación
Zuyderland Medisch Centrum, Sittard-Geleen, Limburg, Netherlands

Authors' Report

Crónica del Autor

Los cambios en las citoquinas asociadas a la inflamación local y sistémica debidos a la enfermedad inflamatoria intestinal influyen en la salud ósea.
Enfermedad inflamatoria intestinal e inflamación ósea extraintestinal asociada

La enfermedad inflamatoria intestinal (EII) se asocia con deficiencias nutricionales, disminución de la absorción de nutrientes, disminución de la actividad física. La EII (activa) lleva a un aumento de la generación de una combinación de citoquinas inflamatorias, potencialmente perjudiciales para el hueso, al igual que el tratamiento de la EII con corticosteroides que se utiliza habitualmente. Estos factores combinados provocan la osteoporosis y el aumento del riesgo de fractura ósea. Se recomiendan estrategias de protección ósea.
Crónica del Autor

Imprimir nota

Bibliographic references
Referencias bibliográficas

1.van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen DHE, Wolters A, Masclee AAM, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM. A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort-Can Diagnostic Factors Explain the Increase in IBD Incidence? J Crohns Colitis. 1;11(10):1169-1179, Oct 2017. doi: 10.1093/ecco-jcc/jjx055. PMID: 28430884.
2.Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, Lukas C. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 29(11):2389-2397, Nov 2018 . doi: 10.1007/s00198-018-4586-6. Epub 2018 Jun 16. PMID: 29909470.
3.Briot K, Roux C. Inflammation, bone loss and fracture risk in spondyloarthritis. RMD Open 14;1(1):e000052, Jul 2015 . doi: 10.1136/rmdopen-2015-000052. PMID: 26509065; PMCID: PMC4613172.
4. Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 9(4):251-7, Dic 2011. doi: 10.1007/s11914-011-0077-9. PMID: 21935582.
5. Souza PP, Brechter AB, Reis RI, Costa CA, Lundberg P, Lerner UH. IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol 169(2):400-12, May 2013. doi: 10.1111/bph.12116. PMID: 23351078; PMCID: PMC3651665.
6. Bravenboer N, Oostlander AE, van Bodegraven AA. Bone loss in patients with inflammatory bowel disease: cause, detection and treatment. Curr Opin Gastroenterol 1;37(2):128-134, Mar 2021. doi: 10.1097/MOG.0000000000000710. PMID: 33332916.
7. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res17(4):695-702, .Abr 2002. doi: 10.1359/jbmr.2002.17.4.695. PMID: 11918227.
8. Kinoshita H, Miyakoshi N, Kashiwagura T, Kasukawa Y, Sugimura Y, Shimada Y. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol 27(4):582-586, Jul 2017. doi: 10.1080/14397595.2016.1232776. Epub 2016 Sep 23. PMID: 27659808.
9. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 15;102(8):1627-33, Oct 1998. doi: 10.1172/JCI3914. PMID: 9788977; PMCID: PMC509014.

Other articles written by the author A.A van Bodegraven
Otros artículos de A.A van Bodegraven

vanBodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, et al., on behalf of the Dutch Initiative on Crohn and Colitis (ICC). Treatment of bone loss in osteopenic patients with Crohn's disease; a double blind, randomized trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation (Crohn and Bone Study). Gut 63:1424-1430, 2014.
Oostlander AE, Bravenboer N, van Essen HW, Klein-Nulend J, Lems WF, Schulten BA, et al., Dutch Initiative on Crohn and Colitis (ICC). Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. J Cell Biochem113:2424-2431, 2012.
Oostlander AE, Everts V, Schoenmaker T, Bravenboer N, van Vliet SJ, van Bodegraven AA, et al. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss. J Cell Biochem 113:260-268, 2012.
Bakker SF, Dik VK, Witte BI, Lips P, Roos JC, van Bodegraven AA. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation. J Crohns Colitis 7:377-384, 2013.
Oostlander AE, Bravenboer N, Sohl E, Holzmann PJ, van der Woude CJ, Dijkstra G, et al., on behalf of the Dutch Initiative on Crohn and Colitis (ICC). Histomorphometric analysis reveals reduced bone mass and bone formating in patients with quiescent Crohn's Disease. Gastroenterology 140:116-123, 2011.
Beekman KM, Veldhuis-Vlug AG, van der Veen A, den Heijer M, Maas M, Kerckhofs G, et al. The effect of PPAR-gamma inhibition on bone marrow adipose tissue and bone in C3H/HeJ mice. Am J PhysiolEndocrinolMetab 316(1):E96-E105, 2019.
Bastidas-Coral AP, Bakker AD, Zandieh-Doulabi B, Kleverlaan CJ, Bravenboer N, Forouzanfar T, Klein-Nulend J. Cytokines TNF-alpha, IL-6, IL-17F, and IL-4 differentially affect osteogenic differentiation of human adipose stem cells. Stem Cells Int 2016:1318256, 2016.

SIIC System of Assisted Editing (SSEA)
/ Sistema SIIC de Edición Asistida (SSEA)

A.A van Bodegraven was invited by SIIC on
A.A van Bodegraven fue invitado por SIIC el
2020, october 29
  The authors' report was accepted on
La crónica del autor fue aprobada el
2023, july 12
The authors' report was accepted on
La crónica del autor fue aprobada el
2023, july 12
Published in siicsalud
Publicado en siicsalud
2023, october 10

The article is strictly related to the following sections of siicsalud
El artículo se relaciona estrictamente con las siguientes secciones de siicsalud

/ Gastroenterología
/ Inmunología

and secondarily related to the following sections

y secundariamente con las siguientes secciones

Endocrinology and Metabolism
Endocrinología y Metabolismo

Osteoporosis and Bone Disorders
Osteoporosis y Osteopatías Médicas

Information about the full text
Acerca del trabajo completo

Perspective on skeletal health in inflammatory bowel disease

Author / Autor
N Bravenboer1

1, Location Vrije Universiteit, Amsterdam, Países Bajos

Access to the original source
Osteoporosis International

Article URL:
/ URL del artículo:

URL of Abstract:
/ URL del abstract:

URL of Abstract page in Medline:
/ URL del abstract en Medline:

URL of Abstract page in Scielo:
/ URL del abstract en Scielo:

URL of Abstract page in Scopus:
/ URL del abstract en Scopus:

URL of Abstract page in Embase:
/ URL del abstract en Embase:

Other data bases:
/ Otras bases de datos:

siic DB:
/ siic DB: